KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT ...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window And in this ...

The deadliest cancers just met their match. A revolutionary cancer vaccine prevents the devastating relapses that have made KRAS-mutated tumors nearly impossible to cure, offering genuine hope to ...

Researchers at MUSC Hollings Cancer Center have discovered why a powerful cancer-causing gene mutation rarely appears in pancreatic tumors. The study, published in Cancer Research Communications, ...

Mutations in KRAS drive PDAC. (A) Illustration depicting different stages of PDAC, in which tumors originating in the pancreas (stage 1) first extend to lymph nodes and bile ducts (stage 2), then ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today ...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...